Orthopedic uses of teriparatide

被引：51

作者：

Bukata S.V. ^{[1
]}

Puzas J.E. ^{[1
]}

机构：

[1] School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, 601 Elmwood Avenue

来源：

Current Osteoporosis Reports | 2010年 / 8卷 / 1期

关键词：

Fracture; Orthopedic; Osteoporosis; Parathyroid hormone; Teriparatide;

D O I：

10.1007/s11914-010-0006-3

中图分类号：

学科分类号：

摘要：

Teriparatide is a drug currently approved for treating patients with osteoporosis who are at high risk for future fracture. In the treatment of osteoporosis, teriparatide works as an anabolic agent stimulating bone formation throughout the skeleton by principally enhancing osteoblastderived bone formation relative to osteoclast-derived bone resorption. The net effect is increased bone mass. For patients with a fracture, a similar process of increased bone formation is required transiently at the fracture site for repair. Teriparatide has been investigated in animal models and in patients as a potential agent to enhance fracture repair. In addition, evidence that teriparatide enhances chondrogenesis has generated interest in using the agent for articular cartilage repair. Research is currently underway to understand the effects teriparatide may have on mesenchymal stem cells, and on other effects that have been reported anecdotally in patients using the drug for osteoporosis care, including the healing of fracture nonunions and a decreased incidence of back pain. We review the current animal and human reports available on the uses of teriparatide in musculoskeletal diseases beyond osteoporosis. © Springer Science+Business Media, LLC 2010.

引用

页码：28 / 33

页数：5

共 26 条

[1] Burge R.T., Dawson-Hughes B., Solomon D., Et al., Incidence and economic burden of osteoporotic fractures in the United States, 2005-2025, J Bone Min Res, 2007, 22, pp. 465-475
[2] Kent G.N., Loveridge N., Reeve J., Et al., Pharmacokinetics of synthetic human parathyroid hormone 1-34 in man measured by cytochemical bioassay and radioimmunoassay, Clin Sci (Lond), 68, pp. 171-177, (1985)
[3] Hock J.M., Gera I., Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone, J Bone Miner Res, 7, pp. 65-72, (1992)
[4] Dempster D.W., Cosman F., Kurland E.S., Et al., Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study, J Bone Miner Res, 16, pp. 1846-1853, (2001)
[5] Barnes G.L., Kostenuik P.J., Gerstenfeld L.C., Einhorn T.A., Growth factor regulation of fracture repair, J Bone Miner Res, 14, pp. 1805-1815, (1999)
[6] Simmons D.J., Fracture healing perspectives, Clin Orthop Relat Res, 200, pp. 100-113, (1985)
[7] Kronenberg H.M., Chung U., The parathyroid hormone-related protein and Indian hedgehog feedback loop in the growth plate, Novartis Found Symp, 232, pp. 144-152, (2001)
[8] Andreassen T.T., Ejersted C., Oxlund H., Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures, J Bone Miner Res, 14, pp. 960-968, (1999)
[9] Andreassen T.T., Willick G.E., Morley P., Whitfield J.F., Treatment with parathyroid hormone hPTH(1-34), hPTH (1-31), and monocyclic hPTH(1-31) enhances fracture strength and callus amount after withdrawal fracture strength and callus mechanical quality continue to increase, Calcif Tissue Int, 74, pp. 351-356, (2004)
[10] Alkhiary Y.M., Gerstenfeld L.C., Krall E., Et al., Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34), J Bone Joint Surg Am, 87, pp. 731-741, (2005)

← 1 2 3 →